Literature DB >> 10869530

Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats.

J E Bishop1, L A Kiernan, H E Montgomery, P Gohlke, J R McEwan.   

Abstract

OBJECTIVES: Elevated systemic arterial blood pressure is associated with left ventricular hypertrophy and fibrosis. It has been suggested that both circulating and local myocardial renin-angiotensin systems play a role in mediating these responses. Here we describe the natural history of ventricular hypertrophy and fibrosis in the transgenic (mRen2)27 rat--a monogenetic model--which has a high tissue expression of the murine renin transgene, and suffers severe hypertension. We further explored the relative contribution of both hypertensive burden and circulating and tissue renin-angiotensin systems to the fibrotic process.
METHODS: The transgenic rats were treated from 28 days old with (1) a hypotensive dose of the ACE inhibitor ramipril which inhibited both tissue and circulating ACE activity, (2) the calcium antagonist amlodipine, or (3) a non-hypotensive dose of ramipril which inhibited about 60% of tissue ACE activity with little effect on circulating ACE. Normotensive Sprague-Dawley rats were used as controls.
RESULTS: The transgenics developed left ventricular hypertrophy along with perivascular and interstitial fibrosis which became progressively worse up to 24 weeks of age. Both the high dose of ramipril and amlodipine prevented the hypertrophy and fibrosis, whereas tissue ACE inhibition without lowering blood pressure had no effect, and actually led to a worsening of the fibrosis by 24 weeks.
CONCLUSIONS: These results suggest that the development of left ventricular hypertrophy and fibrosis in the transgenic (mRen2)27 rat are regulated by blood pressure and not activity of the renin-angiotensin systems and that progression of fibrosis at 24 weeks involves a mechanism unrelated to local renin-angiotensin activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869530     DOI: 10.1016/s0008-6363(00)00063-8

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  7 in total

Review 1.  Endothelin antagonism in experimental ischemic heart failure: hemodynamic, structural and neurohumoral effects.

Authors:  P Mulder; V Richard; C Thuillez
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

2.  Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.

Authors:  J W Knowles; G Esposito; L Mao; J R Hagaman; J E Fox; O Smithies; H A Rockman; N Maeda
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

3.  Association of Liver Fibrosis With Cardiovascular Diseases in the General Population: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Mohammad R Ostovaneh; Bharath Ambale-Venkatesh; Tomoki Fuji; Hooman Bakhshi; Ravi Shah; Venkatesh L Murthy; Russell P Tracy; Eliseo Guallar; Colin O Wu; David A Bluemke; João A C Lima
Journal:  Circ Cardiovasc Imaging       Date:  2018-03       Impact factor: 7.792

4.  Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture.

Authors:  Zhi Xu; Francis J Castellino; Victoria A Ploplis
Journal:  Blood       Date:  2009-12-15       Impact factor: 22.113

5.  Reduced expression of GSTM2 and increased oxidative stress in spontaneously hypertensive rat.

Authors:  Si-Gui Zhou; Ping Wang; Rong-Biao Pi; Jie Gao; Jia-Jia Fu; Jian Fang; Jia Qin; Hui-Jie Zhang; Rui-Fang Li; Shao-Rui Chen; Fu-Tian Tang; Pei-Qing Liu
Journal:  Mol Cell Biochem       Date:  2007-11-16       Impact factor: 3.396

6.  Angiotensin-Converting Enzyme Inhibitors Reduce Uterine Fibroid Incidence in Hypertensive Women.

Authors:  Nicole M Fischer; Tim O Nieuwenhuis; Bhuchitra Singh; Gayane Yenokyan; James H Segars
Journal:  J Clin Endocrinol Metab       Date:  2021-01-23       Impact factor: 5.958

7.  Systemic hypertension among women with uterine leiomyomata: potential final common pathways of target end-organ remodeling.

Authors:  Marc A Silver; Rashmi Raghuvir; Bohdan Fedirko; Denise Elser
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-11       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.